Merck faces double threat to lose up to half of its revenue, could a small study with DRTS save it?

Pristine_Hurry_4693 · 2026-02-25T15:34:50+00:00

=== SUMMARY === - The post discusses the dual threats facing Merck (MRK): the upcoming patent cliff for its blockbuster drug Keytruda and the emergence of a competitor, Imfinzi, from AstraZeneca. - The author's thesis is that a potential solution for Merck's revenue problem lies in its collaboration with Alpha Tau Medical (DRTS), whose Alpha DaRT technology, when combined with Keytruda, has shown dramatically improved response rates in a small trial. - Quality assessment: This is speculative analysis based on early-stage clinical trial data. While it connects real-world events (MRK's restructuring, patent cliff) with a potential catalyst (DRTS trial), the conclusion relies heavily on a small study's results scaling successfully and a potential M&A event, which is highly speculative. === SENTIMENT === BULLISH === TRADE IDEAS === TICKER - DIRECTION | confidence: 0.90 | sentiment: +1.00 Speaker: u/Pristine_Hurry_4693 Thesis: 1. THE FACT: A small trial combining Merck's Keytruda with DRTS's Alpha DaRT technology showed a 100% response rate in treated patients, a massive improvement over Keytruda's 19% standalone rate. 2. THE BRIDGE: This outstanding result could make Alpha DaRT a crucial component for Merck to protect its multi-billion dollar cancer franchise post-patent cliff, potentially leading to a partnership or acquisition of DRTS by Merck. 3. THE VERDICT: DRTS is a speculative buy based on the potential for its technology to significantly enhance the efficacy of a leading cancer drug, creating a compelling M&A or partnership narrative with a major pharmaceutical company like Merck. 4. RISKS: The highly promising results from the small trial may not be replicated in larger, more rigorous Phase 3 trials. The company is a small-cap biotech, which carries inherent volatility and clinical trial risk. Timeframe: medium-term Key Points: - Keytruda + DRTS combo showed 100% response rate in small trial - Could solve Merck's upcoming Keytruda patent cliff problem - Poten

AI Summary

Summary

The post discusses the dual threats facing Merck (MRK): the upcoming patent cliff for its blockbuster drug Keytruda and the emergence of a competitor, Imfinzi, from AstraZeneca.
The author's thesis is that a potential solution for Merck's revenue problem lies in its collaboration with Alpha Tau Medical (DRTS), whose Alpha DaRT technology, when combined with Keytruda, has shown dramatically improved response rates in a small trial.
Quality assessment: This is speculative analysis based on early-stage clinical trial data. While it connects real-world events (MRK's restructuring, patent cliff) with a potential catalyst (DRTS trial), the conclusion relies heavily on a small study's results scaling successfully and a potential M&A event, which is highly speculative.

Score 47

Comments 31

Upvote % 93%

▶ Full Post Text

Merck announced this week that it is creating a separate cancer business, as it braces for the loss of patent protection on Keytruda, the cancer treatment that accounts for nearly half of the company’s revenue.

Merck is taking steps to evolve the structure of its Human Health organization, creating two separate divisions, one for cancer and one for the rest.

Why now? They are facing two threats to the revenue they get from Keytruda, the #1 selling drug in the world (not just for cancer, #1 overall and about half of Mercks revenue).

The first threat is the “patent cliff” everyone is talking about, meaning they will lose the exclusivity they have for Keytruda, allowing others to create their own version of Keytruda.

The second threat is that for the first time, there is a potential competitor, Imfinzi by AstraZeneca (using PD-L1 instead of PD-1), and once the first competitor succeeds and the consensus is broken, other competitors start popping up as well.

Merck creating the cancer business means they are looking for solutions, exploring M&amp;A for example, which brings up the idea of Alpha Tau Medical (NASDAQ: DRTS).

Merck is already running a trial combining Keytruda with Alpha DaRT by DRTS, and the results are outstanding.

Instead of a 19% response rate for Keytruda alone, a small sample size trial with DRTS boosted the numbers all the way to 100% response rate (it was reported as 75% response rate, which is also amazing, but that took into account patients that died before treated by DRTS, but of those that were treated all responded).

So while Keytruda is loosing its exclusivity and facing its first real competitor, boosting the results from 19% to 100% (and from 5% complete response to 50% complete response), could be what not only saves the revenue for Merck but could even spark growth.

Now the bear case would be Merck unable to manage the new transition well, getting to the end of the patent unprepared, or the DRTS trial numbers not translating when tested in larger trials.

For me personally I’m not too worried, as Merck stocks have risen since the announcement showing the market has confidence, and the DRTS treatment just got approved in Japan and is already submitting Phase 3 data to the FDA which isn’t a guarantee but is definitely promising.

Summary

▶ Full Post Text

More from Reddit — r/stocks